INVESTMENTS

Biotech firm Kailos Genetics gets backing from IC venture arm In-Q-Tel

Biotechnology firm Kailos Genetics has received an investment from the intelligence community investment arm In-Q-Tel to help further develop a new genetic sequencing laboratory.

Terms of the partnership were not disclosed. IQT seeks to further spur efforts on both the laboratory and cloud-based software used to perform genetic sequencing.

Huntsville, Ala.-based Kailos started in 2010 to advance genetic testing for partners such as hospitals, physicians, laboratories and pharmacies. Kailos' portfolio includes a laboratory information system built to manage samples in a lab environment, perform analytics and give users reports.

Founded in 1999, IQT seeks to identify startup companies whose technologies have potential use in the intelligence community.

About the Author

Ross Wilkers is a senior staff writer for Washington Technology. He can be reached at rwilkers@washingtontechnology.com. Follow him on Twitter: @rosswilkers. Also find and connect with him on LinkedIn.

Reader Comments

Please post your comments here. Comments are moderated, so they may not appear immediately after submitting. We will not post comments that we consider abusive or off-topic.

Please type the letters/numbers you see above

What is your e-mail address?

My e-mail address is:

Do you have a password?

Forgot your password? Click here
close

Trending

  • POWER TRAINING: How to engage your customers

    Don't miss our Aug. 2 Washington Technology Power Training session on Mastering Stakeholder Engagement, where you'll learned the critical skills you need to more fully connect with your customers and win more business. Read More

  • PROJECT 38 PODCAST

    In our latest Project 38 Podcast, editor Nick Wakeman interviews Tom Romeo, the leader of Maximus Federal about how it has zoomed up the 2019 Top 100. Read More

contracts DB

Washington Technology Daily

Sign up for our newsletter.

Terms and Privacy Policy consent

I agree to this site's Privacy Policy.